ticker stringclasses 50
values | dt stringclasses 13
values | form stringclasses 1
value | impact_domain stringclasses 8
values | impact_severity stringclasses 3
values | risk stringlengths 41 102 | risk_category stringclasses 14
values | risk_driver stringlengths 11 58 | risk_text stringlengths 94 14.7k |
|---|---|---|---|---|---|---|---|---|
AAPL | 20250927 | 10k | operations | high | Geopolitical instability and trade disputes affecting manufacturing and supply chain | supply_chain | geopolitical_instability_and_trade_disputes | Political events, trade and other international disputes, geopolitical tensions, conflict, terrorism, natural disasters, public health issues, industrial accidents and other business interruptions can have a material adverse effect on the Company and its customers, employees, suppliers, contract manufacturers, logistic... |
AAPL | 20250927 | 10k | operations | high | Business interruptions affecting global operations and supply chain | operational | business_interruptions | Many of the Company's operations, retail stores and facilities, as well as critical business operations of the Company's suppliers and contract manufacturers, are in locations that are prone to earthquakes and other natural disasters. Global climate change is resulting in certain types of natural disasters and extreme ... |
AAPL | 20250927 | 10k | revenue | high | Intense market competition affecting product innovation and development | competition | intense_market_competition | The Company's products and services are offered in highly competitive global markets. These markets are characterized by aggressive price competition, downward pressure on gross margins, continual improvement in product performance, and price sensitivity on the part of consumers and businesses. These markets are furthe... |
AAPL | 20250927 | 10k | revenue | high | IP enforcement challenges affecting competitive advantage and product margins | intellectual_property | ip_enforcement_challenges | The Company's ability to compete successfully also depends on the effective protection and enforcement of its intellectual property rights. Regulatory requirements, government investigations and litigation can force the Company to withdraw from, or modify its products and services for, certain countries and limit its a... |
AAPL | 20250927 | 10k | revenue | high | Intense market competition affecting revenue and market share | competition | intense_market_competition | The Company's products and services face substantial competition from companies that have significant technical, marketing, distribution and other resources, as well as established hardware, software and service offerings. In addition, the Company faces significant competition as competitors imitate the Company's produ... |
AAPL | 20250927 | 10k | revenue | high | Product innovation cycles affecting market competitiveness | product | product_innovation_cycles | Due to the highly volatile and competitive nature of the markets and industries in which the Company competes, the Company must continually introduce new products, services and technologies, enhance existing products and services, effectively stimulate customer demand for new and upgraded products and services, navigat... |
AAPL | 20250927 | 10k | operations | high | Supply chain concentration affecting production and distribution control | supply_chain | supply_chain_concentration | A significant majority of the Company's manufacturing is performed in whole or in part by outsourcing partners located primarily in China mainland, India, Japan, South Korea, Taiwan and Vietnam, in addition to sourcing from partners and facilities located in the U.S. The Company relies on single-source partners in the ... |
AAPL | 20250927 | 10k | operations | high | Supplier concentration and shortages affecting component availability | supply_chain | supplier_concentration_and_shortages | Because the Company currently obtains certain components from single or limited sources, the Company is subject to significant supply and pricing risks. Many components, including those that are available from multiple sources, are at times subject to industry-wide shortages and significant commodity pricing fluctuatio... |
AAPL | 20250927 | 10k | operations | high | Design and manufacturing defects affecting product and service reliability | product | design_and_manufacturing_defects | The Company offers complex hardware and software products and services that can be affected by design and manufacturing defects. Sophisticated operating system software and applications, such as those offered by the Company, often have issues that can unexpectedly interfere with the intended operation of hardware or so... |
AAPL | 20250927 | 10k | operations | medium | Product obsolescence affecting inventory and capital asset valuations | financial | product_obsolescence | The Company records a write-down for product and component inventories if cost exceeds net realizable value. The Company reviews other assets, including capital assets held at its suppliers' facilities, inventory prepayments and other long-lived assets, for impairment whenever events or circumstances indicate the asset... |
AAPL | 20250927 | 10k | operations | medium | Inaccurate demand forecasting affecting inventory levels | supply_chain | inaccurate_demand_forecasting | The Company orders components for its products and builds inventory in advance of product announcements and shipments. Manufacturing purchase obligations cover the Company's forecasted component and manufacturing requirements, typically for periods up to 150 days. Because the Company's markets are volatile, competitive... |
AAPL | 20250927 | 10k | operations | high | Third-party intellectual property licensing affecting product availability | intellectual_property | third-party_intellectual_property_licensing | The Company's products and services include technology or intellectual property that must be licensed from third parties. In addition, because of technological changes in the industries in which the Company currently competes or in the future may compete, current extensive intellectual property coverage and the rapid r... |
AAPL | 20250927 | 10k | revenue | high | Third-party application availability affecting consumer demand for products | product | third-party_application_availability | The Company believes decisions by customers to purchase its hardware products depend in part on the availability of third-party software applications and services. Third-party developers may discontinue the development and maintenance of software applications and services for the Company's products. If third-party soft... |
AAPL | 20250927 | 10k | product_delivery | high | Licensing availability affecting digital content offerings | supply_chain | licensing_availability | The Company contracts with numerous third parties to offer their digital content to customers. This includes the right to sell, or offer subscriptions to, third-party content, as well as the right to incorporate specific content into the Company's own services. The licensing or other distribution arrangements for this ... |
AAPL | 20250927 | 10k | operations | medium | Intense talent competition affecting key personnel retention | staff | intense_talent_competition | Much of the Company's future success depends on the talents and efforts of its team members and the continued availability and service of key personnel, including its Chief Executive Officer, executive team and other highly skilled employees. Experienced personnel in the technology industry are in high demand and compe... |
AAPL | 20250927 | 10k | operations | high | Regulatory changes and talent competition affecting workforce recruitment and retention | staff | regulatory_changes_and_talent_competition | In addition to competition for talent, workforce dynamics are constantly evolving and the Company must navigate changes effectively in order to achieve its strategic initiatives. Laws and regulations, including immigration, labor and employment laws and export controls, among others, can materially adversely affect the... |
AAPL | 20250927 | 10k | operations | medium | Cultural deterioration affecting employee recruitment and retention | staff | cultural_deterioration | The Company believes that its distinctive and inclusive culture is a significant driver of its success. If the Company is unable to nurture its culture, it could materially adversely affect the Company's ability to recruit and retain the highly skilled employees who are critical to its success, and could otherwise mate... |
AAPL | 20250927 | 10k | revenue | high | Third-party reseller dependency affecting product distribution and sales | operational | third-party_reseller_dependency | The Company distributes its products and certain of its services through cellular network carriers and other resellers, many of which distribute products and services from competitors. Resellers offer financing, installment payment plans or subsidies for users' purchases of devices, and such plans may be discontinued o... |
AAPL | 20250927 | 10k | operations | high | Information technology disruptions affecting business operations and supply chain | technology | information_technology_disruptions | The Company and its global supply chain are dependent on complex information technology systems and are exposed to information technology system failures or network disruptions caused by natural disasters, accidents, power disruptions, telecommunications failures, acts of terrorism or war, computer viruses, physical or... |
AAPL | 20250927 | 10k | operations | high | Cyber attacks affecting sensitive data and business operations | cybersecurity | cyber_attacks | The Company's business requires it to use and store confidential information, including personal and sensitive health and financial information with respect to the Company's customers and employees. The Company devotes significant resources to systems and data security, including through the use of encryption and other... |
AAPL | 20250927 | 10k | operations | medium | Strategic investments and acquisitions affecting operational and financial performance | operational | strategic_investments_and_acquisitions | The Company has invested, and in the future may invest, in new business strategies, commercial relationships and acquisitions. Such endeavors may involve significant risks and uncertainties, including distraction of management from current operations, greater-than-expected liabilities and expenses, economic, political,... |
AAPL | 20250927 | 10k | operations | high | Litigation and government investigations affecting business operations | legal | litigation_and_government_investigations | The Company is subject to various claims, legal proceedings and government investigations that have arisen in the ordinary course of business and have not yet been fully resolved, and new matters may arise in the future. In addition, the Company enters into agreements that include indemnification provisions that can su... |
AAPL | 20250927 | 10k | compliance | high | Regulatory changes affecting global business operations and product compliance | regulatory | regulatory_changes | The Company's global operations are subject to complex and changing laws and regulations worldwide on subjects including antitrust; privacy, data security and data localization; online safety; age verification; consumer protection; advertising, sales, billing and e-commerce; financial services and technology; product l... |
AAPL | 20250927 | 10k | reputation | medium | Stakeholder ESG expectations affecting corporate reputation | regulatory | stakeholder_esg_expectations | Various stakeholders, including governments, regulators, investors, employees, customers and others, have differing expectations about a wide range of social and other issues related to the Company's business. The Company makes statements about its values, including the environmental and societal impact of its business... |
AAPL | 20250927 | 10k | revenue | high | Regulatory changes and antitrust litigation affecting business operations and revenue | regulatory | regulatory_changes_and_antitrust_litigation | From time to time, the Company has made changes to its business, including actions taken in response to litigation, competition, market conditions and legal and regulatory requirements. The Company expects to make further business changes in the future. For example, in the U.S., the Company has implemented changes to h... |
AAPL | 20250927 | 10k | compliance | high | Evolving data protection regulations affecting business operations | regulatory | evolving_data_protection_regulations | The Company is subject to an increasing number of federal, state and international laws relating to the collection, use, retention, protection and transfer of various types of personal data. In many cases, these laws apply not only to third-party transactions, but also restrict transfers of personal data among the Comp... |
AAPL | 20250927 | 10k | compliance | high | Regulatory changes affecting product compliance and business operations | regulatory | regulatory_changes | The Company is also subject to new and changing laws and regulations regarding online safety, including enhanced protections for minors and mandatory age verification requirements. These laws and regulations can increase regulatory risks by requiring complex compliance measures and significant modifications to the Comp... |
AAPL | 20250927 | 10k | revenue | high | Market volatility and cost pressures affecting gross margin performance | financial | market_volatility_and_cost_pressures | The Company's gross margins vary significantly across its products, services, geographic segments and distribution channels and can change over time. The Company's net sales and gross margins are subject to volatility and downward pressure due to a variety of factors, including: continued industry-wide global product p... |
AAPL | 20250927 | 10k | revenue | high | Foreign exchange rate fluctuations affecting international financial performance | financial | foreign_exchange_rate_fluctuations | The Company's primary exposure to movements in foreign exchange rates relates to non–U.S. dollar–denominated sales, cost of sales and operating expenses worldwide. Gross margins on the Company's products in foreign countries and on products that include components obtained from foreign suppliers have in the past been a... |
AAPL | 20250927 | 10k | liquidity | medium | Market and economic volatility affecting cash and investment values | financial | market_and_economic_volatility | The Company's investments can be negatively affected by changes in liquidity, credit deterioration, financial results, market and economic conditions, political risk, sovereign risk, interest rate fluctuations or other factors. As a result, the value and liquidity of the Company's cash, cash equivalents and marketable ... |
AAPL | 20250927 | 10k | liquidity | medium | Concentration of credit risk affecting trade and vendor receivables | financial | concentration_of_credit_risk | The Company distributes its products and certain of its services through third-party cellular network carriers and other resellers. The Company also sells its products and services directly to small and mid-sized businesses and education, enterprise and government customers. A substantial majority of the Company's outs... |
AAPL | 20250927 | 10k | operations | medium | Tax law changes and examinations affecting financial performance | regulatory | tax_law_changes_and_examinations | The Company is subject to taxes in the U.S. and numerous foreign jurisdictions, including Ireland and Singapore, where a number of the Company's subsidiaries are organized. Due to economic and political conditions, tax laws and tax rates for income taxes and other non-income taxes in various jurisdictions may be subjec... |
AAPL | 20250927 | 10k | liquidity | medium | Stock price volatility affecting share repurchases | market | stock_price_volatility | The Company's stock has experienced substantial price volatility in the past and may continue to do so in the future. Additionally, the Company, the technology industry and the stock market as a whole have, from time to time, experienced extreme stock price and volume fluctuations that have affected stock prices in way... |
AAPL | 20250927 | 10k | reputation | medium | Unmet performance and dividend expectations affecting stock price | market | unmet_performance_and_dividend_expectations | The Company believes the price of its stock should reflect expectations of future growth and profitability. The Company also believes the price of its stock should reflect expectations that its cash dividend will continue at current levels or grow, and that its current share repurchase program will be fully consummated... |
ABBV | 20251231 | 10k | revenue | high | Patent expiration affecting market exclusivity of pharmaceutical products | intellectual_property | patent_expiration | AbbVie relies on patent, trademark and other intellectual property protection in the discovery, development, manufacturing and sale of its products. In particular, patent protection is, in the aggregate, important in AbbVie's marketing of pharmaceutical products in the United States and most major markets outside of th... |
ABBV | 20251231 | 10k | revenue | high | Product concentration affecting revenue stability | product | product_concentration | A significant portion of AbbVie's revenues and operating earnings are derived from two major products. Specifically, Skyrizi and Rinvoq each represented greater than 10% of AbbVie's total net revenues and, in aggregate, these products accounted for approximately 42% of total net revenues in 2025. |
ABBV | 20251231 | 10k | revenue | high | Intellectual property challenges affecting market exclusivity | intellectual_property | intellectual_property_challenges | Third parties or government authorities may challenge or seek to invalidate or circumvent AbbVie's patents and patent applications. For example, manufacturers of generic pharmaceutical products file, and may continue to file, Abbreviated New Drug Applications with the FDA seeking to market generic forms of AbbVie's pro... |
ABBV | 20251231 | 10k | revenue | high | Intellectual property infringement claims affecting product commercialization | intellectual_property | intellectual_property_infringement_claims | Third parties may claim that an AbbVie product infringes upon their intellectual property. In addition, in its pursuit of valid business opportunities, AbbVie may be required to challenge intellectual property rights held by others that it believes were improperly granted. Resolving an intellectual property infringemen... |
ABBV | 20251231 | 10k | revenue | high | Product development failure affecting future revenue streams | product | product_development_failure | To remain competitive, AbbVie must continue to launch new products and new indications and/or brand extensions for existing products. Such launches must generate revenue sufficient both to cover its substantial research and development costs and to replace revenues of profitable products that are lost to or displaced b... |
ABBV | 20251231 | 10k | revenue | high | Pricing pressure affecting product revenue | regulatory | pricing_pressure | Cost-containment efforts by governments and private organizations are described in greater detail in Item 1, "Business—Regulation—Commercialization, Distribution and Manufacturing." To the extent these cost containment efforts are not offset by greater demand, increased patient access to health care, or other factors, ... |
ABBV | 20251231 | 10k | revenue | high | Regulatory price controls affecting product revenue | regulatory | regulatory_price_controls | In particular, the IRA will have the effect of reducing prices and reimbursements for certain of our products, which could significantly impact AbbVie's results of operations. Under the IRA, HHS can effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. General... |
ABBV | 20251231 | 10k | revenue | high | Government pricing regulations affecting pharmaceutical revenue | regulatory | government_pricing_regulations | In addition to the pricing mechanisms established under the IRA, governments and other payers may pursue or implement additional approaches intended to reduce pharmaceutical costs, including arrangements or frameworks that reference international prices, most-favored-nation (MFN) concepts, or other comparative pricing ... |
ABBV | 20251231 | 10k | revenue | high | PBM negotiation leverage affecting product pricing and market access | market | pbm_negotiation_leverage | The potential for continuing changes to the health care system in the United States and the increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid and private sector beneficiaries, including pharmacy benefit managers (PBMs) and managed care organizations may result in additional pricing p... |
ABBV | 20251231 | 10k | revenue | high | Government pricing regulations affecting pharmaceutical revenue and profitability | regulatory | government_pricing_regulations | In major markets worldwide, governments play a significant role in funding health care services and determining the pricing and reimbursement of pharmaceutical products. Consequently, in those markets, AbbVie is subject to government decision-making and budgetary actions with respect to its products. In particular, man... |
ABBV | 20251231 | 10k | revenue | high | Government pricing initiatives affecting net revenue | regulatory | government_pricing_initiatives | Rebates related to government programs, such as fee-for-service Medicaid or Medicaid managed care programs, arise from laws and regulations. AbbVie cannot predict with certainty whether additional government initiatives to contain health care costs or other factors could lead to new or modified regulatory or contractua... |
ABBV | 20251231 | 10k | revenue | high | Intermediary consolidation affecting pricing and reimbursement levels | market | intermediary_consolidation | Consolidation and vertical integration among PBMs, managed care organizations and other supply chain intermediaries has increased their purchasing power and ability to influence formulary placement and reimbursement levels. A limited number of these entities negotiate pricing, rebates and patient access terms on behalf... |
ABBV | 20251231 | 10k | revenue | high | Formulary placement restrictions affecting product access and revenue | market | formulary_placement_restrictions | These entities employ formulary management and utilization tools, including formulary exclusions, step therapy requirements, prior authorization protocols and tiered placement decisions, that could limit or delay patient access to our products, potentially increase patient cost-sharing and/or shift utilization to compe... |
ABBV | 20251231 | 10k | revenue | high | Regulatory changes to PBM practices affecting pricing and revenue | regulatory | regulatory_changes_to_pbm_practices | PBM business practices, rebate structures and pricing arrangements are also subject to change as a result of enforcement actions, regulatory settlements, legislation or other government actions. Government-mandated changes to PBM rebate methodologies, formulary design or pricing transparency practices could affect our ... |
ABBV | 20251231 | 10k | operations | high | Partner performance and disputes affecting product pipeline development | operational | partner_performance_and_disputes | AbbVie depends on alliances and joint ventures with pharmaceutical and biotechnology companies for a portion of the products in its near-term pharmaceutical pipeline. Failures by these parties to meet their contractual, regulatory, or other obligations to AbbVie, or any disruption in the relationships between AbbVie an... |
ABBV | 20251231 | 10k | operations | high | Biological manufacturing and regulatory complexities affecting product commercialization | operational | biological_manufacturing_and_regulatory_complexities | The successful discovery, development, manufacturing and sale of biologics is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and current governmental regulations res... |
ABBV | 20251231 | 10k | operations | medium | Trade policy changes affecting international supply chain operations | supply_chain | trade_policy_changes | AbbVie operates in a global environment and relies on complex international supply chains for the development, manufacture, and distribution of its products, including the sourcing of active pharmaceutical ingredients and key materials. Changes in global trade policy, including the potential imposition of import or exp... |
ABBV | 20251231 | 10k | revenue | high | Market competition and generic entry affecting product revenue | competition | market_competition_and_generic_entry | AbbVie competes with other research-based pharmaceutical and biotechnology companies that research, develop, manufacture, market and sell proprietary pharmaceutical products and biologics. All of these competitors may introduce new products or develop technological advances that compete with AbbVie's products in therap... |
ABBV | 20251231 | 10k | operations | high | Manufacturing complexities affecting product availability | operational | manufacturing_complexities | The manufacture of many of AbbVie's products is a highly exacting and complex process, due in part to strict regulatory requirements. Problems may arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, delay... |
ABBV | 20251231 | 10k | product_delivery | high | Single-source supplier dependency affecting manufacturing and product delivery | supply_chain | single-source_supplier_dependency | AbbVie uses raw materials and components in its pharmaceutical and biologic manufacturing processes that may be sourced from single suppliers. The failure of AbbVie's suppliers, and particularly its single-source suppliers, to fulfill their contractual obligations in a timely manner or as a result of regulatory noncomp... |
ABBV | 20251231 | 10k | operations | high | Third-party reliance affecting business operations and product delivery | supply_chain | third-party_reliance | AbbVie relies on suppliers, vendors and other third party service providers to research, develop, manufacture, commercialize, promote and sell its products. In addition, AbbVie relies on third party service providers for support of its information technology services. Reliance on third party manufacturers reduces AbbVi... |
ABBV | 20251231 | 10k | revenue | medium | New safety information affecting product labeling and use | regulatory | new_safety_information | Pharmaceutical products receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Additional, and perhaps more extensive, studies may also be conducted, which may be spons... |
ABBV | 20251231 | 10k | revenue | high | Safety or efficacy issues affecting product market acceptance | product | safety_or_efficacy_issues | information on a product's label or narrow its approved indication, either of which could reduce the product's market acceptance. If safety or efficacy issues with an AbbVie product arise, sales of the product could be halted by AbbVie or by regulatory authorities and regulatory action could be taken by such regulatory... |
ABBV | 20251231 | 10k | operations | high | Product liability litigation affecting financial performance and reputation | legal | product_liability_litigation | In the ordinary course of business, AbbVie is the subject of product liability claims and lawsuits alleging that AbbVie's current or historical products or the products of other companies that it promotes have resulted or could result in an unsafe condition for or injury to patients. Product liability claims and lawsui... |
ABBV | 20251231 | 10k | operations | medium | Legal proceedings and investigations affecting operations and reputation | legal | legal_proceedings_and_investigations | AbbVie is also the subject of other claims, legal proceedings and investigations in the ordinary course of business, which relate to intellectual property, commercial, securities and other matters. Adverse outcomes in such claims, legal proceedings and investigations may also adversely affect AbbVie's business, results... |
ABBV | 20251231 | 10k | revenue | high | Regulatory approval delays affecting product commercialization | regulatory | regulatory_approval_delays | AbbVie's products are subject to rigorous regulation by numerous international, supranational, federal and state authorities, as described in Item 1, "Business—Regulation—Discovery and Clinical Development," "Business—Regulation—Commercialization, Distribution and Manufacturing,"and "Business—Regulation—Medical Devices... |
ABBV | 20251231 | 10k | compliance | high | Regulatory changes affecting healthcare industry operations | regulatory | regulatory_changes | The U.S. healthcare industry, in particular, is highly regulated and subject to frequent and substantial regulatory changes. It is expected that the U.S. healthcare industry will continue to be subject to increasing regulation as well as political and legal action, as future proposals to reform the healthcare system ar... |
ABBV | 20251231 | 10k | operations | high | Regulatory non-compliance affecting product availability and manufacturing operations | regulatory | regulatory_non-compliance | In addition, AbbVie cannot guarantee that it will remain compliant with applicable regulatory requirements once approval has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling and advertising and post-marketing reporting, includin... |
ABBV | 20251231 | 10k | operations | high | Regulatory non-compliance affecting healthcare program participation and business operations | regulatory | regulatory_non-compliance | The health care industry is subject to federal, state and international laws and regulations pertaining to government benefit program reimbursements, rebates, price reporting and regulation and health care fraud and abuse. In the United States, these laws include anti-kickback and false claims laws, the Medicaid Rebate... |
ABBV | 20251231 | 10k | revenue | high | Regulatory pricing mandates affecting product revenue | regulatory | regulatory_pricing_mandates | The 340B Drug Pricing Program requires participating manufacturers to offer discounts to covered entities and growth in entities claiming entitlement to 340B pricing has increased the portion of our sales subject to such discounts. Manufacturer policies designed to improve program integrity have been subject to enforce... |
ABBV | 20251231 | 10k | revenue | high | International market volatility affecting global revenue generation | economic | international_market_volatility | AbbVie's business is subject to risks associated with doing business internationally, including in emerging markets. Net revenues outside of the United States made up approximately 24% of AbbVie's total net revenues in 2025. The risks associated with AbbVie's operations outside the United States include: fluctuations i... |
ABBV | 20251231 | 10k | revenue | high | Ineffective product commercialization affecting market demand and revenue | market | ineffective_product_commercialization | AbbVie must effectively and profitably commercialize its principal products by creating and meeting continued market demand; achieving market acceptance and generating product sales; ensuring that the active pharmaceutical ingredient(s) for a product and the finished product are manufactured in sufficient quantities an... |
ABBV | 20251231 | 10k | operations | medium | Strategic transactions affecting operational and financial performance | operational | strategic_transactions | AbbVie from time to time pursues acquisitions, technology licensing arrangements, joint ventures and strategic alliances, and/or disposes of some of its assets, as part of its business strategy. AbbVie may not complete these transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the ... |
ABBV | 20251231 | 10k | revenue | high | Distributor concentration affecting revenue stability | customer | distributor_concentration | In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States. If one of its significant wholesale distributors encounters financial or other difficulties, such distributor may decrease ... |
ABBV | 20251231 | 10k | liquidity | high | High debt levels affecting cash flow and financial flexibility | financial | high_debt_levels | The amount of debt that AbbVie has incurred and intends to incur could have important consequences to AbbVie and its investors. These consequences include, among other things, requiring a portion of AbbVie's cash flow from operations to make interest payments on this debt and reducing the cash flow available to fund ca... |
ABBV | 20251231 | 10k | liquidity | medium | Limited financing availability affecting business expansion and product development | financial | limited_financing_availability | AbbVie may need additional financing in the future to meet its capital needs or to make opportunistic acquisitions. For example, it may need to increase its investment in research and development activities. The capital and credit markets may experience extreme volatility and disruption, which may lead to uncertainty a... |
ABBV | 20251231 | 10k | operations | high | Cyber attacks affecting information technology systems and sensitive data | cybersecurity | cyber_attacks | AbbVie relies on sophisticated software applications and complex information technology systems (including cloud services) to operate its business, which are inherently vulnerable to malicious intrusion, random attack, loss of data privacy, disruption, degradation or breakdown. Certain of these applications and systems... |
ABBV | 20251231 | 10k | operations | medium | AI implementation challenges affecting operational efficiency and competitiveness | technology | ai_implementation_challenges | Additionally, AbbVie utilizes AI and other emerging technologies in select applications to support its operations. These technologies may present opportunities for AbbVie's business but may also entail risks, including that AI-generated analyses utilized by AbbVie could be deficient or exacerbate regulatory, cybersecur... |
ABBV | 20251231 | 10k | operations | high | Impairment charges affecting intangible assets and goodwill | financial | impairment_charges | A significant amount of AbbVie's total assets is related to acquired intangibles and goodwill. As of December 31, 2025, the carrying value of AbbVie's developed product rights and other intangible assets was $52.6 billion and the carrying value of AbbVie's goodwill was $35.6 billion. AbbVie's developed product rights a... |
ABBV | 20251231 | 10k | operations | medium | Intense talent competition affecting key personnel retention | staff | intense_talent_competition | AbbVie's success is largely dependent on its continued ability to attract, develop and retain diverse, highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical research and development, governmental regulation and commercialization. Competition for qualified perso... |
ABBV | 20251231 | 10k | reputation | high | Counterfeit and diverted products affecting brand reputation and revenue | product | counterfeit_and_diverted_products | Third parties may illegally obtain, distribute, and sell counterfeit or illegally diverted from their intended market versions of AbbVie products. These versions of product would not meet AbbVie's rigorous manufacturing, testing, distribution and quality standards. A patient who receives a counterfeit, stolen, or diver... |
ABBV | 20251231 | 10k | operations | medium | Macroeconomic and regulatory shifts affecting financial performance and operational stability | economic | macroeconomic_and_regulatory_shifts | Many other factors can affect AbbVie's results of operations, cash flows and financial condition, including: changes in or interpretations of laws and regulations, including changes in accounting standards, taxation requirements, product marketing application standards, data privacy laws, particularly in the European U... |
ABBV | 20251231 | 10k | liquidity | medium | Operational cash flow and board discretion affecting dividend payments | financial | operational_cash_flow_and_board_discretion | Although AbbVie expects to pay regular cash dividends, the timing, declaration, amount and payment of future dividends to stockholders will fall within the discretion of AbbVie's board of directors. The board's decisions regarding the payment of dividends will depend on many factors, such as AbbVie's financial conditio... |
ABBV | 20251231 | 10k | liquidity | medium | Equity issuances affecting stockholder ownership and earnings per share | financial | equity_issuances | In the future, a stockholder's percentage ownership in AbbVie may be diluted because of equity issuances for capital market transactions, equity awards that AbbVie will be granting to AbbVie's directors, officers and employees, acquisitions or other purposes. AbbVie anticipates its compensation committee will grant add... |
ABBV | 20251231 | 10k | liquidity | medium | Preferred stock issuance affecting common stock value and voting power | financial | preferred_stock_issuance | In addition, AbbVie's amended and restated certificate of incorporation authorizes AbbVie to issue, without the approval of AbbVie's stockholders, one or more classes or series of preferred stock having such designation, powers, preferences and relative, participating, optional and other special rights, including prefe... |
ABBV | 20251231 | 10k | liquidity | low | Anti-takeover provisions affecting potential business combinations | legal | anti-takeover_provisions | AbbVie's amended and restated certificate of incorporation and amended and restated by-laws contain, and Delaware law contains, provisions that are intended to deter coercive takeover practices and inadequate takeover bids by encouraging prospective acquirors to negotiate with AbbVie's board of directors rather than to... |
ABBV | 20251231 | 10k | operations | medium | Anti-takeover provisions affecting potential corporate acquisition opportunities | legal | anti-takeover_provisions | AbbVie believes these provisions protect its stockholders from coercive or otherwise unfair takeover tactics by requiring potential acquirors to negotiate with AbbVie's board of directors and by providing AbbVie's board of directors with more time to assess any acquisition proposal. These provisions are not intended to... |
ABBV | 20251231 | 10k | revenue | medium | Uncertain business factors affecting projected financial results | financial | uncertain_business_factors | This Annual Report on Form 10-K contains certain forward-looking statements regarding business strategies, market potential, future financial performance and other matters. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify "forward... |
ADBE | 20251128 | 10k | revenue | high | Technological innovation failure affecting product competitiveness and revenue | technology | technological_innovation_failure | We operate in rapidly evolving industries and expect the pace of innovation to continue to accelerate. We must continually introduce new and enhance existing solutions to retain customers and attract new customers. Developing new solutions is complex, requires significant investment and operational costs and may not be... |
ADBE | 20251128 | 10k | revenue | high | Intense market competition affecting customer acquisition and revenue growth | competition | intense_market_competition | The markets for our solutions are rapidly evolving and intensely competitive. We expect competition to continue to intensify. Our numerous competitors include companies of various sizes and both public and private companies, including large, global companies and smaller companies with more specialized focuses, new entr... |
ADBE | 20251128 | 10k | reputation | medium | AI development and governance issues affecting product integrity and reputation | technology | ai_development_and_governance_issues | Social, ethical and operational issues relating to the use of AI, including generative AI and agentic AI, in our solutions may result in reputational harm, liability and additional costs. We are increasingly incorporating AI technologies, developed by us and by third parties, into many of our solutions. If our AI devel... |
ADBE | 20251128 | 10k | compliance | high | Regulatory changes affecting AI product development and compliance costs | regulatory | regulatory_changes | Jurisdictions around the world are developing and passing new regulations that apply specifically to the use of AI. For example, the U.S. AI regulatory framework remains in development and has been introduced at the federal level through executive orders and legislation has been introduced and enacted at the state leve... |
ADBE | 20251128 | 10k | compliance | medium | Third-party AI models affecting intellectual property and legal compliance | intellectual_property | third-party_ai_models | Additionally, as we offer more third-party AI models in our solutions, we face risks inherent in how third-party AI models used in our solutions have been developed and deployed, including situations in which the third party may lack a proper license or consent for the training data used for their model. The use and av... |
ADBE | 20251128 | 10k | revenue | high | AI development and regulatory uncertainty affecting operational margins and revenue | technology | ai_development_and_regulatory_uncertainty | In addition, new competition regulations on AI development and deployment could impose new requirements on our markets that could impact our business and financial results. Uncertainty around new and evolving AI uses may require significant, additional investment to develop models and proprietary datasets, responsible-... |
ADBE | 20251128 | 10k | reputation | medium | Reputational harm affecting brand value and customer demand | market | reputational_harm | We believe our reputation and brands have been, and we expect them to continue to be, important to our business and financial results. Maintaining and enhancing our brands may require us to make substantial investments and these investments may not be successful. We have experienced, and may in the future experience, r... |
ADBE | 20251128 | 10k | operations | medium | Business acquisitions affecting operational performance and financial results | operational | business_acquisitions | We have acquired and may continue to acquire businesses, products, talent and technologies as part of our business strategy. Acquisitions, investments and other strategic transactions involve numerous risks and uncertainties, the occurrence of which may have an adverse effect on our business. These risks and uncertaint... |
ADBE | 20251128 | 10k | operations | medium | Talent competition affecting workforce retention and operational performance | staff | talent_competition | Much of our future success depends on the continued service, availability and performance of our senior management and highly skilled personnel across all levels of our organization. Our senior management has acquired specialized knowledge and skills with respect to our business, and the loss of any of these individual... |
ADBE | 20251128 | 10k | operations | high | Infrastructure or service failures affecting business operations and service delivery | operational | infrastructure_or_service_failures | Much of our business, including our online store at adobe.com, our cloud solutions and various business processes such as our enterprise resource planning system and customer and sales support, relies on hardware and services that are hosted, managed and controlled directly by us or third-party service providers to be ... |
ADBE | 20251128 | 10k | service | medium | Data center migration disruptions affecting solution delivery | operational | data_center_migration_disruptions | Occasionally, we migrate data among data centers and to third-party hosted environments. If a transition among data centers or to third-party service providers encounters unexpected interruptions, unforeseen complexity or unplanned disruptions despite precautions undertaken during the process, this may impair our deliv... |
ADBE | 20251128 | 10k | service | high | System infrastructure failures affecting data reliability and service delivery | operational | system_infrastructure_failures | It is also possible that hardware or software failures or errors in our systems (or those of our third-party service providers) could result in data loss or corruption, cause the information that we collect or maintain to be incomplete or contain inaccuracies that our customers regard as significant, or cause us to fai... |
ADBE | 20251128 | 10k | service | medium | Inadequate infrastructure capacity planning affecting service availability | operational | inadequate_infrastructure_capacity_planning | If we fail to plan infrastructure capacity appropriately and expand it proportionally with the needs of our customer and user base, and we experience a rapid and significant demand on the capacity of our data centers or those of third parties, service outages or performance issues could occur, which may impact our cust... |
ADBE | 20251128 | 10k | operations | high | Cybersecurity incidents affecting information systems and data security | cybersecurity | cybersecurity_incidents | Our solutions collect, store, manage and otherwise process third-party data, including our customers' data and our own data. Such solutions as well as our technologies, systems and networks have been subject to, and may in the future be subject to, cyberattacks, computer viruses, ransomware or other malware, fraud, wor... |
ADBE | 20251128 | 10k | revenue | medium | Fraudulent activities affecting revenue and reputation | operational | fraudulent_activities | Malicious actors may also engage in fraudulent or abusive activities through our solutions, including unauthorized use of accounts through stolen credentials, use of stolen credit cards or other payment vehicles, failure to pay for services accessed, or other activities that violate our terms of service. While we activ... |
ADBE | 20251128 | 10k | reputation | medium | Customer cybersecurity breaches affecting brand reputation and operational resources | cybersecurity | customer_cybersecurity_breaches | Our customers may also adopt security measures to protect their computer systems and their instances of our software from attack and may suffer a cybersecurity breach on their own systems, unrelated to our systems. Even if such breach is unrelated to our security systems, solutions or programs, such breach could cause ... |
ADBE | 20251128 | 10k | revenue | medium | Sales channel management affecting revenue generation | operational | sales_channel_management | We rely on our direct sales channel and a number of third-party distributors and sales partners to distribute our solutions. The successful management of these relationships is a complex, global process. We sell many solutions through our direct sales force. Risks associated with this sales channel include challenges r... |
ADBE | 20251128 | 10k | operations | medium | Third-party service dependencies affecting operational continuity | operational | third-party_service_dependencies | We also rely on third-party service providers and technologies to deliver our solutions and business operations and to operate critical business systems, such as cloud-based infrastructure, data center facilities, generative AI, large language models, encryption and authentication technology, company email and other co... |
End of preview. Expand in Data Studio
Penumbra AI SEC 10-K Risk Factor Disclosures (S&P 500, FY2025-2026)
Dataset Summary
This dataset contains a sample of 2,683 individual risk factor disclosures from the most recent Form 10-K filing of 50 S&P 500 companies (fiscal year ends ranging from May 2025 to February 2026). Each record is a single risk driver — one discrete point a company disclosed under "Risk Factors" — together with the verbatim disclosure text and a set of machine generated categorical labels (domain, severity, category).
Supported Tasks
- Text classification: predict
risk_category,impact_domain, orimpact_severityfromrisk_text. - Financial NLP / risk analysis: cross-company comparison of disclosed risk themes.
Not designed as a benchmark — labels are pipeline output, not human-annotated ground truth (see Limitations).
Languages
English (en). Filing text is drawn from US SEC filings.
Dataset Structure
Data Instance
{
"ticker": "JPM",
"dt": "20251231",
"form": "10k",
"impact_domain": "compliance",
"impact_severity": "high",
"risk": "Regulatory and legal changes affecting business operations",
"risk_category": "regulatory",
"risk_driver": "regulatory_and_legal_changes",
"risk_text": "risks, including the impact of extensive supervision and regulation, as well as changes to or in the application, interpretation or enforcement of applicable law..."
}
Data Fields
| Field | Type | Description |
|---|---|---|
ticker |
string | Uppercase ticker symbol (e.g. JPM) |
dt |
string | Fiscal year end date of the filing, YYYYMMDD |
form |
string | SEC form type (always 10k in this file) |
impact_domain |
string | Business impact area, lowercased, e.g. operations, revenue, liquidity, compliance, reputation |
impact_severity |
string | Severity, lowercased: low / medium / high |
risk |
string | Short title summarizing the risk driver |
risk_category |
string | Category, lowercased, e.g. regulatory, operational, financial, market, cybersecurity |
risk_driver |
string | Short snake_case identifier for the risk driver, lowercased, unique-ish within a filing |
risk_text |
string | The disclosure text itself, extracted from the filing (verbatim or near-verbatim) |
Data Splits
Single split, no train/test division: train (2,683 rows).
Coverage
- 50 companies, one ticker's most recent 10-K each (not a historical/multi-year set — see Limitations)
- Filing fiscal-year-end dates: 2025-05-31 to 2026-02-01
impact_domaindistribution: operations (984), revenue (875), liquidity (274), compliance (271), product_delivery (116), reputation (116), technology (28), service (19)impact_severitydistribution: high (1,389), medium (1,275), low (19)risk_categorydistribution (top 5): regulatory (688), operational (453), financial (345), market (170), intellectual_property (126)
Dataset Creation
Source Data
Text is sourced from Risk Factors sections of Form 10-K annual reports filed with the SEC via EDGAR, for a set of ~50 S&P 500 companies.
Annotations
impact_domain, impact_severity, risk_category, risk, and risk_driver are pipeline-assigned labels — they are not sourced from the filing text itself and were not human-reviewed. risk_text is extracted directly from the filing.
Personal and Sensitive Information
None. All source text is public company disclosure filed with a US federal regulator.
Considerations for Using the Data
Known Limitations
- Labels are machine generated. Treat them as approximate.
- Single period only. This file has one 10-K per company (the most recent), not the multi-year filing history the underlying pipeline is capable of producing — it does not capture year-over-year change.
Licensing
This dataset is released under CC-BY-4.0: free to use, including commercially, with attribution. This is a sample drawn from a larger underlying dataset; the sample is shared openly, with commercial licensing available for the full dataset on request.
Additional Information
Dataset Curators
Penumbra AI (https://penumbra.software) Contact us here or email hf-data
- Downloads last month
- 47